苯丙氨酸羟化酶
四氢生物蝶呤
背景(考古学)
苯丙氨酸
疾病
人口
医学
生物
药理学
内分泌学
内科学
生物化学
化学
环境卫生
古生物学
氨基酸
一氧化氮
一氧化氮合酶
作者
Ramón Dı́az-Trelles,Carlos G. Pérez‐García
标识
DOI:10.1016/bs.ircmb.2022.04.008
摘要
Phenylketonuria (PKU) is a metabolic rare disease characterized by a failure of the body to clear out the high levels of Phenylalanine (Phe), leading to devastating neurological defects and growth retardation. PKU was discovered in 1934 by AsbjrØrn FØlling, and even though there have been continuous efforts from the scientific community to find therapeutic approaches to modulate the high levels of phenylalanine found in the body of the PKU patients, an efficient therapy still needs to be developed. Current standard of care includes low phenylalanine diets, but the strict restrictions for patients and families makes it very difficult to adequately being implemented. FDA has approved two drugs to help reduce Phe levels in PKU patients: an enzyme substitution therapy, Palynziq® (PEGylated recombinant phenylalanine ammonia lyase), and Kuvan®, a supplemental tetrahydrobiopterin (BH4) cofactor that enhances residual enzyme activity. Both treatments are restricted to certain PKU patients' population, and, therefore, there are still high unmet needs for most of the patients. The present review will focus on current advancements in lipid nanoparticles (LNP)-mRNA technologies and their potential in treating the root cause of PKU, a therapeutic approach that will be analyzed in the context of other promising therapeutic approaches that are been developed for PKU.
科研通智能强力驱动
Strongly Powered by AbleSci AI